Minervax ApS

Minervax aps email format

Verified email-pattern data for Minervax Aps is currently limited. You can still use the company insights and contact sections below.
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability. Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.

Company Details

Employees
72
Address
Ole Maaløes Vej 3, Copenhagen,capital Region 2200,denmark
Email
pb****@****vax.com
Industry
Biotechnology
HQ
Copenhagen, Capital Region
Looking for a particular Minervax ApS employee's phone or email?

Minervax Aps Questions

Explore related pages

Related company profiles:

Top Minervax ApS Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant